



Hepato-Pancreatico-Biliary Cancer Symposium 2022

PROGRAM SCHEDULE

Friday, October 21, 2022

8:00 a.m., PDT Registration, Breakfast and Exhibits

8:40 **Welcome Announcements**
Tanios Bekaii-Saab, M.D. and Mitesh J. Borad, M.D., *Mayo Clinic*

SESSION I **Diagnostic Dilemmas, Management of Premalignant Conditions and Genomic Risk for HPB Cancers**

MODERATOR: G. Dan Duda, D.M.D., Ph.D., *Massachusetts General Hospital*

8:50 **Hepatobiliary Malignancy: Surveillance and Role of Liver Transplantation**
Bashar A. Aqel, M.D., *Mayo Clinic*

9:15 **Genetic Risk Predisposition, Screening and Management for Conditions Related to HPB Cancers**
Doug Riegert-Johnson, M.D., *Mayo Clinic*

9:40 **Translational Research in Fibrolamellar Hepatocellular Cancer**
Sanford M. Simon, M.D., *Rockefeller University*

10:05 **Discussion; Q & A**

10:15 Break and Exhibits

SESSION II **Precision Medicine in HPB Cancers**

MODERATOR: Mitesh J. Borad, M.D., *Mayo Clinic*

10:35 **Clinical Applications of FGFR and IDH1 Inhibitors in BTC**
Milind M. Javle, M.D., *MD Anderson Cancer Center*

10:55 **Emerging Targets in BTC**
James J. Harding, M.D., *Memorial Sloan Kettering Cancer Center*

11:15 **Immune Markers in HCC**
Mehmet Akce, M.D., *University of Alabama at Birmingham*

11:35 **ctDNA and Its Emerging Applications in HPB Cancers**
Subham Pant, M.D., *MD Anderson Cancer Center*

11:55 **Discussion; Q & A**



Hepato-Pancreatico-Biliary Cancer Symposium 2022

PROGRAM SCHEDULE

Friday, October 21, 2022 (continued)

12:05 p.m. PDT

Lunch and Exhibits

SESSION III

Controversies and Conundrums in the Treatment of HPB Cancers

MODERATOR:

Tanios Bekaii-Saab, M.D., *Mayo Clinic*

1:00

Dual Checkpoint Inhibitors as Best Option for 1L Treatment of Advanced Hepatocellular Carcinoma

Richard S. Finn, M.D., *Ronald Reagan UCLA Medical Center*

1:10

Anti-angiogenics and Checkpoint Inhibitors as Best Option for 1L Treatment of Advanced Hepatocellular Carcinoma

Anthony B. El-Khoueiry, M.D., *University of Southern California*

1:20

Discussion; Q & A

1:40

Adjuvant Therapy is Standard for Resected BTC

Lionel A. Kankeu Fonkoua, M.D., *Mayo Clinic*

1:50

There is No Role for Adjuvant Therapy in Resected BTC

Bassel El-Rayes, M.D., *University of Alabama Medicine*

2:00

Discussion; Q & A

2:20

Break and Exhibits

SESSION IV

Challenging Cases in Hepatobiliary Cancers: A Multidisciplinary Approach

MODERATOR:

Christopher (Chris) L. Hallemeier, M.D., *Mayo Clinic*

2:45

Discussion Panel:

Daniel H. Ahn, D.O., *Mayo Clinic*

James J. Harding, M.D., *Memorial Sloan Kettering Cancer Center*

Timucin Taner, M.D. Ph.D.

Beau Toskich, M.D., *Mayo Clinic*

3:45

Closing Remarks

Mitesh J. Borad, M.D., *Mayo Clinic*



Hepato-Pancreatico-Biliary Cancer Symposium 2022

PROGRAM SCHEDULE

Saturday, October 22, 2022

7:00 a.m., PDT Breakfast and Exhibits

7:50 **Announcements**
Tanios Bekaii-Saab, M.D., *Mayo Clinic*

SESSION V “Out-of-the-Box” Multidisciplinary Management of HPB Cancers

MODERATOR: Mark J. Truty, M.D., M.S., *Mayo Clinic*

8:00 **The Role of Surgery in Oligometastatic Pancreatico-biliary Cancers**
Matthew John Weiss, M.D., FACS, *Northwell Health*

8:25 **Molecular Staging of Hematogenous and Peritoneal Metastases in Pancreatic Cancer: The Time is Now**
Mark J. Truty, M.D., M.S., *Mayo Clinic*

8:50 **The Role of Transplant for Liver Limited Metastasis**
Timucin Taner, M.D., Ph.D., *Mayo Clinic*

9:15 **Emerging Applications of HAI Pumps in BTC**
Cornelius A. Thiels, D.O., M.B.A., *Mayo Clinic*

9:40 **Discussion; Q & A**

10:05 Break and Exhibits

SESSION VI Challenging Cases in Pancreas Cancer: A Multidisciplinary Approach

MODERATOR: Mark J. Truty, M.D., M.S., *Mayo Clinic*

10:25 **Case Discussion Panel**
Bassel El-Rayes, M.D., *University of Alabama Medicine*
Wen Wee Ma, M.B.B.S., *Mayo Clinic*
Kumar Sandrasegaran, M.B.Ch.B., *Mayo Clinic*
Terence T. Sio, M.D., M.S., *Mayo Clinic*
Mohamad (Bassam) B. Sonbol, M.D., *Mayo Clinic*
Matthew John Weiss, M.D., FACS, *Northwell Health*



Hepato-Pancreatico-Biliary Cancer Symposium 2022

PROGRAM SCHEDULE

Saturday, October 22, 2022 (*continued*)

SESSION VII **Research Platforms to Address the Less Common and Rare Target in HPB Cancer**

MODERATOR: Wen Wee Ma, M.B.B.S., *Mayo Clinic*

11:25 a.m., PDT **Research Platforms in Pancreas Cancer**
Michael Jon Pishvaian, M.D., Ph.D., *Johns Hopkins*

11:45 **Research Platforms in BTC**
Mitesh J. Borad, M.D., *Mayo Clinic*

12:05 p.m. **Discussion; Q&A**

12:20 **Closing Remarks and Adjourn**
Mitesh J. Borad, M.D., *Mayo Clinic*